- Home
- HIMS vs EXEL Comparison
HIMS vs EXEL Comparison
Compare HIMS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMS
- EXEL
- Stock Information
- Founded
- HIMS 2017
- EXEL 1994
- Country
- HIMS United States
- EXEL United States
- Employees
- HIMS N/A
- EXEL 1147
- Industry
- HIMS Medical/Nursing Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIMS Health Care
- EXEL Health Care
- Exchange
- HIMS Nasdaq
- EXEL Nasdaq
- Market Cap
- HIMS 11.6B
- EXEL 10.4B
- IPO Year
- HIMS N/A
- EXEL 2000
- Fundamental
- Price
- HIMS $46.01
- EXEL $38.31
- Analyst Decision
- HIMS Hold
- EXEL Buy
- Analyst Count
- HIMS 11
- EXEL 21
- Target Price
- HIMS $38.30
- EXEL $43.65
- AVG Volume (30 Days)
- HIMS 37.3M
- EXEL 4.0M
- Earning Date
- HIMS 08-04-2025
- EXEL 07-28-2025
- Dividend Yield
- HIMS N/A
- EXEL N/A
- EPS Growth
- HIMS 866.21
- EXEL 81.76
- EPS
- HIMS 0.79
- EXEL 2.08
- Revenue
- HIMS $2,013,538,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- HIMS $62.00
- EXEL $9.88
- Revenue Next Year
- HIMS $20.15
- EXEL $12.59
- P/E Ratio
- HIMS $58.34
- EXEL $18.45
- Revenue Growth
- HIMS 88.69
- EXEL 10.73
- 52 Week Low
- HIMS $13.47
- EXEL $25.12
- 52 Week High
- HIMS $72.98
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- HIMS 37.78
- EXEL 41.08
- Support Level
- HIMS $45.28
- EXEL $37.01
- Resistance Level
- HIMS $70.43
- EXEL $38.78
- Average True Range (ATR)
- HIMS 3.87
- EXEL 1.12
- MACD
- HIMS -1.54
- EXEL 0.07
- Stochastic Oscillator
- HIMS 2.90
- EXEL 83.79
About HIMS Hims & Hers Health Inc.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.